Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Crescent Biopharma (CBIO) Accumulated Depreciation & Amortization (2016 - 2023)

Crescent Biopharma (CBIO) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $2.5 million as the latest value for Q3 2023.

  • Quarterly Accumulated Depreciation & Amortization rose 7.23% to $2.5 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Sep 2023, up 7.23% year-over-year, with the annual reading at $2.4 million for FY2022, 2.74% up from the prior year.
  • Accumulated Depreciation & Amortization for Q3 2023 was $2.5 million at Crescent Biopharma, up from $2.5 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $2.5 million in Q3 2023, with the low at $1.9 million in Q1 2020.
  • Average Accumulated Depreciation & Amortization over 4 years is $2.3 million, with a median of $2.3 million recorded in 2022.
  • The sharpest move saw Accumulated Depreciation & Amortization grew 12.03% in 2022, then grew 2.03% in 2023.
  • Over 4 years, Accumulated Depreciation & Amortization stood at $2.1 million in 2020, then increased by 8.94% to $2.3 million in 2021, then grew by 2.74% to $2.4 million in 2022, then grew by 5.18% to $2.5 million in 2023.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $2.5 million, $2.5 million, and $2.4 million for Q3 2023, Q2 2023, and Q1 2023 respectively.